左卡尼丁联合促红细胞生成素治疗肾性贫血的临床观察  

Effects of L-carnitine Combined with Erythropoietin on Treatment of Renal Anemia

作　　者：杨俊生[1,2] 王军[1,2] 覃学勇[1,2] 刘莉莉[1,2] 

机构地区：[1]南方医科大学附属柳州医院 [2]柳州市柳铁中心医院肾内科,广西柳州545007

出　　处：《热带医学杂志》2012年第11期1357-1358,1361,共3页Journal of Tropical Medicine

摘　　要：目的观察左卡尼丁联合促红细胞生成素(rhEPO)治疗维持性血液透析患者肾性贫血的疗效。方法将40例维持性血液透析患者随机分成治疗组和对照组,每组各20例,均采用相同血液透析方式进行透析,且血透后每周给予重组人促红细胞生成素(rhEPO)100～150U/kg皮下注射,但治疗组每次透析结束后静脉注射左卡尼丁1g,而对照组仅注射促红细胞生成素,疗程12周。结果两组患者的血红蛋白(HB)、红细胞压积(HCT)较治疗前明显升高,治疗组优于对照组(P<0.05);治疗组rhEPO用量较对照组少,两组比较差异有统计学意义(P<0.05);治疗组不良症状发生率较对照组少,差异有统计学意义(P<0.05)。结论左卡尼丁联合促红细胞生成素能显著提高尿毒症血液透析患者贫血的疗效,同时左卡尼丁能减少促红细胞生成素的用量,降低不良反应的发生率。Objective To observe the effect of combined L-carnitine and erythropoietin on treatment of renal anemia over twelve weeks. Methods Forty patients on dialysis were enrolled, and randomly divided into treatment and control groups. All patients were given erythropoietin 100-150 U/kg every week. The patients in treatment group also received L-carnitine after hemodialysis. Result After treatment, the improvements of hemoglobin and hemotcrit of the treatment group were much better than those of the control group （P〈0.05）, and the adverse effects of the treatment patients were mild. Conclusion Combined use L-carnitine with erythropoietin treatment may improve the efficacy and has less side effect.

关 键 词：左卡尼丁 重组人促红细胞生成素 肾性贫血 

分 类 号：R692[医药卫生—泌尿科学]